Physician profile
Elizabeth Sun
NPI 1023087285
$6,351.39
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $129 · 2021: $1,003 · 2022: $1,690 · 2023: $2,033 · 2024: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511 · Education: $43.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.98 |
| Education | $43.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.73 | 2019-2024 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $691.19 | 2019-2024 | Stelara, Remicade, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $675.19 | 2019-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $421.92 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $375.58 | 2019-2023 | Entyvio, Gattex |
| Celgene Corporation | $368.89 | 2021-2023 | Zeposia |
| Pfizer INC. | $331.34 | 2019-2024 | |
| Allergan, INC. | $315.54 | 2019 | |
| Ironwood Pharmaceuticals, INC | $299.07 | 2019-2024 | Linzess |
| Daiichi Sankyo INC. | $285.50 | 2019-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $274.80 | 2020-2023 | |
| Gilead Sciences, INC. | $200.43 | 2019-2023 | |
| Ardelyx, INC. | $195.09 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $144.06 | 2024 | Voquezna |
| Genzyme Corporation | $135.72 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $108.97 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $78.79 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $75.70 | 2021-2023 | Dificid, Zinplava |
| Biofire Diagnostics, LLC | $68.00 | 2019 | |
| Fresenius Kabi USA, LLC | $65.83 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $45.86 | 2019-2022 | |
| Celltrion USA INC. | $43.90 | 2023 | Yuflyma |
| Lilly USA, LLC | $42.80 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $37.81 | 2022 | |
| Digestive Care, INC. | $35.75 | 2022 | |
| Braintree Laboratories, INC. | $22.68 | 2023 | Sutab |
| Sandoz INC. | $22.44 | 2023 | Hyrimoz |
| Boston Scientific Corporation | $18.23 | 2023 | Endoarmor |
| Alfasigma USA, INC. | $17.32 | 2022 | |
| Intra-Sana Laboratories | $16.28 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Concordia Pharmaceuticals INC. | $12.50 | 2019 | |
| Redhill Biopharma INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.